Bayer partners with Hamamatsu

Bayer Schering Pharma of Berlin and Hamamatsu Photonics of Hamamatsu, Japan, have signed a licensing agreement to share their products and expertise in molecular imaging for cancer.

Under the pact, Bayer Schering Pharma will acquire the worldwide exclusive rights for research, development, and commercialization of a group of molecules that specifically bind to malignant tumor cells.

The tracers are labeled with a short-life radionuclide and can be employed for PET imaging. These new PET tracers could help enhance the differentiation of malignant tumors from benign tissue alterations and allow more precise staging of cancer.

Related Reading

Bayer Schering, Epix to end Vasovist partnership, September 4, 2008

Bayer awarded Amerinet deal, April 14, 2008

Bayer announces ship date for VistaTrak, March 13, 2008

Bayer inks molecular imaging deal, February 20, 2008

Bayer launches VistaTrak at RSNA show, December 3, 2007

Copyright © 2009

Page 1 of 435
Next Page